Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) insider transactions

In the twelve months to 10 November 2026, executives and directors of Sagimet Biosciences reported 10 open-market sales of 521,996 shares ($4.9m) and 0 open-market purchases, by 5 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Sagimet Biosciences shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
14 August 2026Kemble GeorgeDirectorOption exercise+326,618$6.36388,779Form 4
14 August 2026Kemble GeorgeDirectorOption exercise+24,369$6.36413,148Form 4
14 August 2026Kemble GeorgeDirectorOpen-market sale−350,987$10.2362,161Form 4
11 August 2026Kemble GeorgeDirectorOption exercise+9,751$6.3671,912Form 4
11 August 2026Kemble GeorgeDirectorOption exercise+10,455$6.3682,367Form 4
11 August 2026Kemble GeorgeDirectorOpen-market sale−20,206$9.9562,161Form 4
20 July 2026Kemble GeorgeDirectorOpen-market sale−18,844$7.4662,161Form 4
20 July 2026Rozek ElizabethChief Legal & Admin. OfficerOpen-market sale−10,545$7.76224,414Form 4
20 July 2026Happel DavidPresident & CEOOpen-market sale−64,051$7.76741,570Form 4
19 February 2026Chauche ThierryChief Financial OfficerGrant or award+44,000—59,688Form 4
19 February 2026Happel DavidPresident & CEOGrant or award+128,000—805,621Form 4
19 February 2026Martins Eduardo BrunoChief Medical OfficerGrant or award+44,000—147,296Form 4
19 February 2026Rozek ElizabethChief Legal & Admin. OfficerGrant or award+44,000—234,959Form 4
10 February 2026Rozek ElizabethChief Legal & Admin. OfficerOpen-market sale−2,622$5.36190,959Form 4
10 February 2026Martins Eduardo BrunoChief Medical OfficerOpen-market sale−3,640$5.36103,296Form 4
10 February 2026Chauche ThierryChief Financial OfficerOpen-market sale−1,312$5.3615,688Form 4
10 February 2026Happel DavidPresident & CEOOpen-market sale−12,101$5.36677,621Form 4
20 November 2025Kemble GeorgeExecutive ChairmanOpen-market sale, 10b5-1 plan−37,688$7.6981,005Form 4
4 November 2025Rozek ElizabethChief Legal & Admin. OfficerGrant or award+9,855—193,581Form 4
21 July 2025Rozek ElizabethGeneral Counsel and CCOOpen-market sale−10,780$9.13183,726Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Sagimet Biosciences page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.